SutroVax announced the addition of Dr. Bruce Forrest to the company's preeminent Scientific Advisory Board. Dr. Forrest has over 25 years of global leadership in pharmaceutical development, with extensive specialty expertise in conjugate vaccine development. As a Senior Vice President at Wyeth Pharmaceuticals until 2010, he was responsible for all post-discovery development activities in Wyeth Vaccines Research leading both clinical and pharmaceutical science development contributing to the development of Prevnar 13®.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.39 USD | +0.52% |
|
+5.91% | +31.19% |
Jul. 02 | Vaxcyte, Inc. Appoints John P. Furey as Member of the Compensation Committee | CI |
Jul. 02 | Vaxcyte Appoints John Furey to Board of Directors | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.19% | 8.96B | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.12% | 27.95B | |
-19.51% | 20.5B | |
-15.78% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- PCVX Stock
- News Vaxcyte, Inc.
- SutroVax Announces Appointment of Dr. Bruce Forrest to Scientific Advisory Board